Kiran Mazumdar Shaw hands Biocon reins to niece Claire and targets semaglutide push from FY28

The leadership handover starts now, semaglutide later

Biocon’s Executive Chairperson Kiran Mazumdar-Shaw has mapped a five-year succession plan, naming her niece Claire Mazumdar as successor. The company expects a strong FY27 launch calendar, especially in the second half, driven by its “diabesity” franchise. It also reports significant debt reduction and will channel more operational cash flow toward further deleveraging as it targets a semaglutide push from FY28.